Prescription Digital Therapeutics, or PDTs, are software-based disease treatments. PDTs are designed to directly treat disease, tested for safety and efficacy in randomized clinical trials, evaluated by the FDA, and prescribed by healthcare providers. PDTs are designed and tested much like traditional prescription drugs with one distinction: rather than swallowing a pill or taking an injection, patients are treated with software.
The leader in Prescription Digital Therapeutics
At Pear, our mission is clear: we are pioneers in PDTs. Our cross-functional team operates at the intersection of biology and software technology. Pear discovers, develops, and delivers clinically validated software to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine.
Multiple products, therapeutic areas, and development stages
Our platform produces products to treat patients suffering from a range of serious diseases. Pear’s lead product, reSET®, works with face-to-face therapy to treat Substance Use Disorder, and was the first PDT to receive market authorization from the FDA to improve disease outcomes. Pear’s second product candidate, reSET-O™ for the treatment of Opioid Use Disorder, is currently under review by the FDA with Breakthrough Designation. Our pipeline is focused on product candidates across development stages that demonstrate large, clinically-relevant treatment effects.
Pear Therapeutics and Sandoz Obtain FDA Market Authorization of reSET-O™ to Treat Opioid Use Disorder.